Home' Australian Pharmacist : Australian Pharmacist January 2015 Contents Australian Pharmacist January 2015 I © Pharmaceutical Society of Australia Ltd.
Layton leaves Chemmart
Chemmart Pharmacy Executive Director,
Jonathan Layton, has left the after more
than 10 years with the company.
EBOS General Manager of Retail Services
Andrew Vidler said it had been ‘a very
hard decision for Jonathan to make.’
‘For the past year, he has been
commuting to Canada to be with
his family and to support his young
son’s education. Understandably, he
has now decided to move to Canada
permanently,’ Mr Vidler said.
‘ While we are very sad to see Jonathan
go we completely understand
and support him in making such a
courageous personal decision.’
Under Mr Layton’s direction, Chemmart
Pharmacy has emerged as a market
leader, particularly in the provision of
professional health services, increasing
sales over the 10-year period from
$320m to $900m in 2013–14. In 2014,
the company opened 26 new Chemmart
Pharmacies – a rate of one new store
every 13 days.
‘Jonathan’s vision and articulation of
the Chemmart brand has been a key to
our success and will ensure the ongoing
success of our brand in the years ahead,’
Mr Vidler said.
Guild welcomes new
The Pharmacy Guild of Australia has
welcomed new measures which ensure
pharmacists only claim for PBS medicines
dispensed from premises which have
been approved by Government.
Through information provided by the
Guild and other sources the Department
of Health had become aware of a small
number of instances where approved
pharmacists appeared to be claiming for
the supply of pharmaceutical benefits
where the supply was not made at or
from approved premises.
The new measures are in the form of
amendments to the National Health
(Pharmaceutical Benefits) (Conditions
of approval for approved pharmacists)
Determination 2007, and became
effective on 1 December 2014.
The National Health Act 1953 allows
for payment of a claim for the supply
of a pharmaceutical benefit where
the supply has been made at or from
premises for which a pharmacist is
approved under the Act. An approved
pharmacist is a pharmacist who is
approved under Part VII of the Act to
supply pharmaceutical benefits at
particular premises (approved premises).
The Act also provides that payment to an
approved pharmacist for the supply of a
pharmaceutical benefit cannot be made
if it was supplied at or from unapproved
premises, or otherwise than in accordance
with a condition of approval.
To emphasise the importance of making
a correct claim, an additional condition
has now been added. The new condition
states that an approved pharmacist
must not make a claim for payment for
the supply of a pharmaceutical benefit
unless the pharmaceutical benefit was
supplied at or from the pharmacist’s
A breach of the conditions of
approval can be deemed an ‘abuse’
of approval and may lead to an
investigation by a Pharmaceutical
Services Federal Committee of Inquiry.
Such an investigation may result in
the suspension or revocation of the
Interim Code authorisation
Medicines Australia (MA) has welcomed
the Australian Competition and
Consumer Commission’s (ACCC) decision
to grant interim authorisation for Code
of Conduct Edition 17.
The interim authorisation will allow
MA’s Code of Conduct Edition 17 to
continue to operate until a final decision
on the authorisation of Code Edition
18 is reached.
‘Medicines Australia welcomes the
ACCC’s recognition that the Code
delivers significant public benefits
by setting a high standard of ethical
conduct for the prescription medicines
industry,’ MA CEO Tim James said.
He said MA will continue to work with
the ACCC to achieve authorisation of
Code Edition 18 early in the New Year.
‘After years of extensive consultation
with industry, consumer groups and
medical groups, MA has proposed a
model that considerably increases
transparency in line with community
‘ The proposed new transparency model
in Code Edition 18 requires MA member
companies to identify doctors by name
and the payments they receive where
permission is granted. MA consulted
extensively with consumer groups and
other stakeholders in developing its
proposed transparency model.’
Links Archive Australian Pharmacist December 2014 Australian Pharmacist February 2015 Navigation Previous Page Next Page